Edition:
United Kingdom

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

24.11USD
13 Dec 2017
Change (% chg)

$-4.41 (-15.46%)
Prev Close
$28.52
Open
$28.50
Day's High
$29.00
Day's Low
$24.01
Volume
33,160
Avg. Vol
--
52-wk High
$51.90
52-wk Low
$22.90

Summary

Name Age Since Current Position

Michael Sinclair

73 2012 Executive Chairman of the Board

Roger Crystal

38 2009 President, Chief Executive Officer, Director

David O'Toole

58 2017 Chief Financial Officer

Arvind Agrawal

2015 Executive Vice President - Medical Affairs

Phil Skolnick

69 2017 Chief Scientific Officer

Ann MacDougall

2016 Director

Gabrielle Silver

42 2016 Director

Thomas Thomas

2016 Director

Michael Porter

IR Contact Officer

Biographies

Name Description

Michael Sinclair

Dr. Michael J. Sinclair is Executive Chairman of the Board of Lightlake Therapeutics Inc. Dr. Sinclair qualified as a physician in 1967, specializing in psychiatry. He has built both private and public healthcare businesses, establishing medical facilities and hospitals in the US, Middle East, East Asia, Australia and UK, including the Portland in London, which was his personal vision to launch the first private hospital in Britain dedicated to treating women and children. He serves on the Board of Overseers (Emeritus) of Tufts University Medical School, where, together with Dean Mort Madoff, he founded the US’ first combined MD/MBA program. Dr. Sinclair has been the Chairman of Symthera Inc., Advanced Oncotherapy Plc., and Emess Biosciences Ltd.

Roger Crystal

Dr. Roger Crystal serves as President, Chief Executive Officer, Director of Lightlake Therapeutics Inc. He has an extensive background in healthcare, having worked as a surgeon in London’s leading hospitals, before transitioning into business. He has experience working in strategy healthcare consulting, serving across several functions in the UK National Health Service and with global pharmaceutical clients. He also has worked in business development with GE Healthcare since October 2010. In addition to his medical degree, he was awarded membership in The Royal College of Surgeons of England and holds an MBA from London Business School. He also has M&A experience at GE Capital and Goldman Sachs. He remains a UK board certified physician.

David O'Toole

Mr. David D. O'Toole is Chief Financial Officer of the company. He has more than 30 years of experience in the accounting and finance sectors, and for nearly half of his career, he has focused on the life sciences industry. From 2014 to 2017, he served as the Chief Financial Officer at Soleno Therapeutics, Inc. (“Soleno”), a company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Mr. O’Toole managed Soleno’s initial public offering in 2014 and raised over $40 million for the company in a number of financing transactions. During the last nine years as the Chief Financial Officer of four life sciences companies, Mr. O’Toole has led numerous M&A and financing transactions. He has significant experience in Securities and Exchange Commission reporting, managing and building finance, treasury and accounting departments, Sarbanes-Oxley Act of 2002 compliance and managing investor relations and commercial operations. Prior to Soleno, Mr. O'Toole served as the Chief Financial Officer at Codexis, Inc. from 2012 to 2014 and Response Genetics, Inc. from 2010 to 2012. Prior to that, from 2008 to 2009, Mr. O'Toole served as Chief Financial Officer at Abraxis BioScience, Inc., which was acquired by Celgene for $2.9 billion. Prior to his Chief Financial Officer experience, Mr. O’Toole spent 24 years in public accounting, including 16 years with the accounting firm of Deloitte & Touche LLP, including 12 years as a partner, and began his career with eight years at the accounting firm of Arthur Andersen. Mr. O'Toole holds a Bachelor of Science degree in accounting from the University of Arizona and is a Certified Public Accountant. As the Company’s Chief Financial Officer, Mr. O’Toole will be responsible for all aspects of financial management for Opiant and will report to Dr. Roger Crystal, the Company’s Chief Executive Officer.

Arvind Agrawal

Mr. Arvind Agrawal is Executive Vice President - Medical Affairs of Lightlake Therapeutics Inc. Mr. Agrawal brings over 20 years of experience in medical and public affairs, scientific communications, and clinical development to Lightlake. During his career, Mr. Agrawal has overseen, managed, and delivered global phase I-IV clinical studies and has extensive experience in the therapeutic areas of addiction, psychiatry, CNS, respiratory, cardiovascular, and diabetes. Prior to joining Lightlake, Mr. Agrawal was Head of Medical Affairs New Products at Mundipharma International, where he made significant advances in the development of a novel treatment for opioid addiction. As European Clinical and Scientific Affairs Director of Reckitt Benckiser Pharmaceuticals, he developed successful strategies leading to highly positive clinical, public, and legislative changes for the cost-effective treatment of opioid dependence. Mr. Agrawal served three years at AstraZeneca plc as European Medical Affairs Manager prior to joining Reckitt Benckiser Pharmaceuticals. Managing a large team of medical managers from across Europe , he was responsible for the lifecycle management of late-stage development and marketed products and communicated new clinical data to a large community of stakeholders. Prior to his appointment at AstraZeneca plc as European Medical Affairs Manager, Mr. Agrawal served as a Therapy Area Specialist and Clinical Study Manager at AstraZeneca plc and a Medical Affairs Manager for GlaxoSmithKline plc, SmithKline Beecham plc, and Wellcome Pharmaceuticals, where he helped to launch pharmaceutical blockbusters Crestor (rosuvastatin) and Avandia (rosiglitazone). Arvind Agrawal holds a MSc in Human & Applied Physiology from King's College, University of London , and serves as the Managing Director of Ekagra Ltd., a pharmaceutical medical affairs consultancy based in the United Kingdom

Phil Skolnick

Dr. Phil Skolnick, Ph.D., D.Sc. (hon.) serves as Chief Scientific Officer of the Company. Dr. Skolnick joins Opiant from the National Institute of Health, where he served as Director of the Division of Therapeutics and Medical Consequences, National Institute of Drug Abuse, since 2010. Prior to joining the NIH, he served as President and Chief Scientific Officer of DOV Pharmaceutical, Inc., and, prior to that, Research Fellow in Neuroscience at Lilly Research Laboratories (LRL), a division of Eli Lilly & Co. Before joining Lilly, Dr. Skolnick served as Chief, Laboratory of Neuroscience at the NIH. Dr. Skolnick earned his Ph.D. from The George Washington University, School of Medicine,Department of Pharmacology and has twice been awarded the D.Sc. honoris causa.

Ann MacDougall

Ms. Ann L. MacDougall is Director of the Company. She has extensive global experience spanning both operating and legal roles for both private and non-profit organizations. Since January 2014, she has served as President of Encore.org, a national organization building a movement for individuals developing second careers in public or non-profit service. From 2007 to December 2013, Ms. MacDougall was Chief Operating Officer of Acumen, an investment fund focused on goods and services for low-income customers. Prior to Acumen, she had a long career managing legal matters at PriceWaterhouseCoopers, including as General Counsel in the U.S. and Deputy General Counsel based in Paris. Ms. MacDougall earned her B.A. at Tufts University and her J.D. at Brooklyn Law School.

Gabrielle Silver

Dr. Gabrielle Silver is Director of the Company. She has extensive experience managing the growth and profitability of pharmaceuticals and diagnostics businesses with a key focus on neurology. Since October 2015, she has served as a partner at Brunswick Group, an advisory firm specializing in critical issues and corporate relations, where she is co-leading the firm’s global pharmaceutical and healthcare offering. From October 2013 to October 2015, she was an executive at GE Healthcare’s Operating Room Solutions business, a new division at GE Healthcare. From September 2010 to October 2013, she was Global Head of Neuroscience/General Medicine Strategic Marketing at GE. In this role, she developed the disease-focused growth strategy across the diagnostics and imaging portfolio. Earlier in her career, Dr. Silver was the director of the CNS Franchise of Eisai Ltd., UK for which she was responsible for growth and profitability of key brands in the UK including Aricept® and Zonegran®. Prior to her tenure at Eisai, she was Therapeutic Area Director of Neuroscience at Bristol-Myers Squibb UK. Dr. Silver received her Bachelor of Science from the University of Bristol and her Bachelor of Medicine and Bachelor of Surgery from the University of London. She is also a Fellow of the Faculty of Pharmaceutical Medicine in the UK.

Thomas Thomas

Mr. Thomas T. Thomas serves as Director of the Company. Mr. Thomas has over 25 years of financial experience in biotechnology, packaged goods, financial services and non-profit organizations. Since 2011, Mr. Thomas has been self-employed providing financial, investment and risk management consulting services to a variety of technology, beverage and food and biotechnology companies. In 2009, Mr. Thomas joined the Stupski Foundation (“Stupski”), as its chief financial officer. In 2010, Mr. Thomas was promoted to chief operating officer and served as Stupski’s interim chief executive officer before leaving Stupski in late 2010 to pursue consulting opportunities. Prior to joining Stupski, Mr. Thomas spent 12 years at Genentech, Inc. (“Genentech”), serving as the company’s corporate treasurer from 2001 to 2006. His executive responsibilities at Genentech included treasury operations, cash and investment management, corporate finance, global procurement, enterprise risk management, business continuity and real estate finance and administration. From 1990 to 1994, Mr. Thomas was a manager of financial strategy with Del Monte Foods and he began his career in 1988 at GE Capital Corporation (“GE”) as an analyst in GE’s corporate finance group, which focused on leveraged buyouts and bankruptcy financing. Mr. Thomas currently serves on the board of trustees of the Cancer Prevention Institute of California and has previously served on the boards of the San Francisco Security Analysts and Hospitality House. He is also a mentor in the Ivy Exec Mentorship Network. Mr. Thomas is a Chartered Financial Analyst and received his Master of Business Administration from the University of Cincinnati, where he was a Graduate Fellow, and a Bachelor of Music from the University of Cincinnati’s College-Conservatory of Music.

Michael Porter

Basic Compensation